Session Details

Speakers, titles, times, and locations of ASGCT presentations

Detailed Program

232: The Novel Autologous AML Vaccine, TriLeukeVax, Stimulates Robust Anti-Leukemic Patient T Cell Responses

Disclosures:  J. Du: None.

Related Abstract

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.